ClinicalTrials.gg
TerminatedNCT01403064Updated May 11, 2021Results posted

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

A Phase 2 interventional study of ALD518 and 0.9% saline in Oral Mucositis, sponsored by CSL Behring. Terminated at 31 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-11.

Sponsored by CSL Behring (part of CSL Limited) · Phase 2, Interventional, and Treatment

Why this study was terminated
due to lack of efficacy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies in Stomatitis with a site in United States — 12 open to participants now, 15 under way, none of them phase 3. Stomatitis · United States.

Enrollment
30th of 73
76 · median 60
Started
2011
with 2 others
Phase 2
33 of 80
2 open now
Registered
29th of 80
by date

Among the 80 studies in Stomatitis with a site in United States, this one is the 30th largest by enrollment of the 73 interventional ones that give a count, is one of 3 that started in 2011, is one of 33 in phase 2, and was the 29th registered.

Stomatitis

306 studies on the registry are indexed under Stomatitis; 75 are open to participants now.

Browse Stomatitis studies →

Open to participants now

12 of the 80 studies in Stomatitis with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 47 Stomatitis studies recruiting now, 21 (45%) set no upper age limit and 22 (47%) stop at 75 or younger; 10 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Stomatitis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of ALD518 in modifying the course of oral mucositis in subjects with head and neck cancer receiving concomitant chemotherapy and radiotherapy

Read the detailed description

This was a Phase 2, placebo-controlled, double-blind study in subjects newly diagnosed with head and neck cancer (who had not received previous treatment for oral mucositis) and who were receiving concomitant chemotherapy and radiotherapy. Subject eligibility, including tumor staging, was assessed during the screening period, which was to occur within 30 days prior to the initiation of radiation therapy. The radiation therapy treatment period was approximately 7 weeks, depending on the subject's prescribed radiation plan. Prior to the randomized portion of the trial, the first 7 subjects enrolled in the study entered a safety run-in evaluation and received a total of 2 doses of open-label clazakizumab 160 mg IV, 4 weeks apart (Day 0 and Week 4 of radiation); these subjects were not eligible for the randomized portion of the study. Subsequent to completion of the safety run-in, eligible subjects were randomized 1:1:1 to treatment with 2 doses of clazakizumab 160 mg, or clazakizumab 320 mg, or placebo, administered IV 3 weeks apart (Day 0 and Week 3 of radiation therapy). All subjects were to be followed for 4 weeks post last day of radiotherapy treatment for the primary efficacy and safety assessments and then for up to an additional 12 months of long-term follow-up.

03

Conditions studied

  • Oral Mucositis

Keywords

  • Oral mucositis; head and neck cancer; chemotherapy; radiotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have recently diagnosed (\< than 6 months prior to screening visit date), confirmed, non- SCC of the oral cavity, oropharynx, hypopharynx or larynx that will be treated with CRT as treatment; subjects with a history of surgical management (approximately 4-6 weeks before RT with sufficient time for post-surgical healing) are eligible
  • Have a plan to receive a continuous course of conventional external beam irradiation delivered by intensity-modulated radiotherapy (IMRT) as single daily fractions of 2.0 to 2.2 Gy, with a cumulative radiation dose between 55 and 72 Gy.
  • Have a plan to receive a standard cisplatin CT regimen administered tri-weekly (80 to 100 mg/m2, on Days 0, 21, and 42) or weekly (30 to 40 mg/m2) or a standard carboplatin regimen administered weekly (100 mg/m2)
  • Have an (ECOG) performance status ≤ 1
  • CRP \< 80 mg/L
  • Have adequate hematopoietic, hepatic, and renal function at the screening visit

Exclusion criteria

Exclusion Criteria:

  • Tumor of the lips, sinuses, salivary glands, nasopharynx or unknown primary tumor
  • disease (M1) Stage IV C
  • Any prior history of head and neck cancer
  • Prior radiation to the head and neck
  • Have had a major surgical procedure, other than for HNC, or significant traumatic injury within 4 weeks prior to the initiation of RT; or anticipation of need for a major surgical procedure during the clinical trial
  • Active infectious disease, excluding oral candidiasis
  • Have OM at the screening visit
  • Have a history of to monoclonal antibody
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Open Label ALD518

    Biological: ALD518

  • Experimental
    ALD518 Dose 1

    Biological: ALD518

  • Experimental
    ALD518 Dose 2

    Biological: ALD518

  • Placebo comparator
    Placebo

    Drug: 0.9% saline

Interventions

  • BiologicalALD518

    IV

  • Drug0.9% saline

    IV Infusion

06

What researchers measure

Primary outcomes

  1. Percent of Participants With Adverse Events, Serious Adverse Events and Clinically Significant Laboratory Abnormalities

    Time frame: Up to 15 months

  2. Number of Participants With Adverse Events, Serious Adverse Events and Clinically Significant Laboratory Abnormalities

    Time frame: Up to 15 months

  3. Percent of Participants With All Grades of Oral Mucositis (OM) at a Radiation Dose of 55 Gy

    Gray (Gy) is used as a unit of the radiation quantity absorbed dose that measures the energy deposited by ionizing radiation in a unit mass of matter being irradiated, and is used for measuring the delivered dose of ionizing radiation in applications such as radiotherapy. The 55 Gy ulcerative OM assessment is defined as the first ulcerative OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in their cumulative dose of radiation being ≥ 55 Gy

    Time frame: Up to 12 weeks

  4. Number of Participants With All Grades of OM at a Radiation Dose of 55 Gy

    The 55 Gy ulcerative OM assessment is defined as the first ulcerative OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in their cumulative dose of radiation being ≥ 55 Gy

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Percent of Participants With Ulcerative OM at Varying Cumulative Radiation Doses (Gy)

    The ulcerative OM assessment at a specific cumulative radiation dose (35 Gy, 45 Gy, 55 Gy or 65 Gy) is defined as the first ulcerative OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in the specific cumulative dose of radiation being ≥35 Gy, ≥45 Gy, ≥55 Gy or≥ 65 Gy

    Time frame: Up to 12 weeks

  2. Number of Participants With Ulcerative OM at Varying Cumulative Radiation Doses (Gy)

    The ulcerative OM assessment at a specific cumulative radiation dose (35 Gy, 45 Gy, 55 Gy or 65 Gy) is defined as the first ulcerative OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in the specific cumulative dose of radiation being ≥35 Gy, ≥45 Gy, ≥55 Gy or≥ 65 Gy

    Time frame: Up to 12 weeks

  3. Percent of Participants With Severe OM at Varying Cumulative Radiation Doses (Gy)

    The severe OM assessment at a specific cumulative radiation dose (35 Gy, 45 Gy, 55 Gy or 65 Gy) is defined as the first severe OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in the specific cumulative dose of radiation being ≥35 Gy, ≥45 Gy, ≥55 Gy or≥ 65 Gy

    Time frame: Measured from onset of OM through Week 12

  4. Number of Participants With Severe OM at Varying Cumulative Radiation Doses (Gy)

    The severe OM assessment at a specific cumulative radiation dose (35 Gy, 45 Gy, 55 Gy or 65 Gy) is defined as the first severe OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in the specific cumulative dose of radiation being ≥35 Gy, ≥45 Gy, ≥55 Gy or≥ 65 Gy

    Time frame: Up to 12 weeks

  5. Duration of Ulcerative and Severe OM

    Time frame: Up to 12 weeks

  6. Time to Onset of Ulcerative and Severe OM

    Time frame: Up to 12 weeks

  7. ALD518 Plasma Concentration at Varying Weeks

    Time frame: Baseline and up to 12 weeks

  8. Oral Mucositis Daily Questionnaire (OMDQ) Overall Health Score at Varying Cumulative Radiation Doses (Gy)

    Scored on a scale from 0 (worst possible overall health) to 10 (perfect overall health). Higher scores represent better overall health.

    Time frame: Baseline and up to 12 weeks

  9. Functional Assessment of Cancer Therapy - Head and Neck (FACT-HN) Questionnaire Overall Assessment Score at Varying Cumulative Radiation Doses (Gy)

    The FACT-HN consists of 28 general + 11 head and neck specific items, each rated on a 0 (not at all) to 4 (very much) Likert type scale. The total score ranges from 0 to 148. Higher scores represent better quality of life.

    Time frame: Baseline and up to 12 weeks

  10. Functional Assessment of Chronic Illness Therapy - Fatigue Questionnaire (FACIT-F) Score at Varying Cumulative Radiation Doses (Gy)

    The responses to the 13 items on the FACIT-F questionnaire are each measured on a 5-point Likert scale from 0 (not at all fatigued) to 4 (very much fatigued). The total score ranges from 0 to 52. Higher scores represent less fatigue.

    Time frame: Baseline and up to 12 weeks

  11. Mean Change From Baseline in C-reactive Protein (CRP) Values at Varying Weeks

    The level of C-reactive protein (CRP), which can be measured in your blood, increases when there's inflammation in your body.

    Time frame: Baseline and up to 12 weeks

07

Results

Posted May 11, 2021

Participant flow

Participant flow — Overall Study
MilestonePlaceboALD518 (160 mg, OL)ALD518 (160 mg, R)ALD518 (320 mg, R)
Started2472322
Completed2371919
Not completed1043
Withdrew: Death0011
Withdrew: Withdrawal by subject0011
Withdrew: Other1021

Outcome measures

PrimaryPercent of Participants With Adverse Events, Serious Adverse Events and Clinically Significant Laboratory Abnormalities
Time frame:
Up to 15 months
Reported as:
Number · percentage of participants
Percent of Participants With Adverse Events, Serious Adverse Events and Clinically Significant Laboratory Abnormalities
percentage of participantsPlaceboALD518 (160 mg)ALD518 (320 mg)
Adverse events (AEs)95.7100100
Serious adverse events30.446.938.1
Clinically significant laboratory abnormalities06.34.8
Treatment-related AEs52.265.657.1
AEs leading to treatment discontinuation03.14.8
PrimaryNumber of Participants With Adverse Events, Serious Adverse Events and Clinically Significant Laboratory Abnormalities
Time frame:
Up to 15 months
Reported as:
Number · participants
Number of Participants With Adverse Events, Serious Adverse Events and Clinically Significant Laboratory Abnormalities
participantsPlaceboALD518 (160 mg)ALD518 (320 mg)
Adverse events (AEs)223221
Serious adverse events7158
Clinically significant laboratory abnormalities021
Treatment-related AEs122112
AEs leading to treatment discontinuation011
PrimaryPercent of Participants With All Grades of Oral Mucositis (OM) at a Radiation Dose of 55 Gy

Gray (Gy) is used as a unit of the radiation quantity absorbed dose that measures the energy deposited by ionizing radiation in a unit mass of matter being irradiated, and is used for measuring the delivered dose of ionizing radiation in applications such as radiotherapy. The 55 Gy ulcerative OM assessment is defined as the first ulcerative OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in their cumulative dose of radiation being ≥ 55 Gy

Time frame:
Up to 12 weeks
Reported as:
Number · percentage of participants
Percent of Participants With All Grades of Oral Mucositis (OM) at a Radiation Dose of 55 Gy
percentage of participantsPlaceboALD518 (160 mg, OL)ALD518 (160 mg, R)ALD518 (320 mg, R)
Percent of Participants With All Grades of Oral Mucositis (OM) at a Radiation Dose of 55 Gy79.271.410077.3
PrimaryNumber of Participants With All Grades of OM at a Radiation Dose of 55 Gy

The 55 Gy ulcerative OM assessment is defined as the first ulcerative OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in their cumulative dose of radiation being ≥ 55 Gy

Time frame:
Up to 12 weeks
Reported as:
Number · participants
Number of Participants With All Grades of OM at a Radiation Dose of 55 Gy
participantsPlaceboALD518 (160 mg, OL)ALD518 (160 mg, R)ALD518 (320 mg, R)
Number of Participants With All Grades of OM at a Radiation Dose of 55 Gy1952317
SecondaryPercent of Participants With Ulcerative OM at Varying Cumulative Radiation Doses (Gy)

The ulcerative OM assessment at a specific cumulative radiation dose (35 Gy, 45 Gy, 55 Gy or 65 Gy) is defined as the first ulcerative OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in the specific cumulative dose of radiation being ≥35 Gy, ≥45 Gy, ≥55 Gy or≥ 65 Gy

Time frame:
Up to 12 weeks
Reported as:
Number · percentage of participants
Percent of Participants With Ulcerative OM at Varying Cumulative Radiation Doses (Gy)
percentage of participantsPlaceboALD518 (160 mg, OL)ALD518 (160 mg, R)ALD518 (320 mg, R)
35 Gy58.385.781.865.0
45 Gy87.585.790.975.0
55 Gy79.271.410075.0
65 Gy83.383.310068.8
SecondaryNumber of Participants With Ulcerative OM at Varying Cumulative Radiation Doses (Gy)

The ulcerative OM assessment at a specific cumulative radiation dose (35 Gy, 45 Gy, 55 Gy or 65 Gy) is defined as the first ulcerative OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in the specific cumulative dose of radiation being ≥35 Gy, ≥45 Gy, ≥55 Gy or≥ 65 Gy

Time frame:
Up to 12 weeks
Reported as:
Number · participants
Number of Participants With Ulcerative OM at Varying Cumulative Radiation Doses (Gy)
participantsPlaceboALD518 (160 mg, OL)ALD518 (160 mg, R)ALD518 (320 mg, R)
35 Gy1461813
45 Gy2162015
55 Gy1952215
65 Gy1551911
SecondaryPercent of Participants With Severe OM at Varying Cumulative Radiation Doses (Gy)

The severe OM assessment at a specific cumulative radiation dose (35 Gy, 45 Gy, 55 Gy or 65 Gy) is defined as the first severe OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in the specific cumulative dose of radiation being ≥35 Gy, ≥45 Gy, ≥55 Gy or≥ 65 Gy

Time frame:
Measured from onset of OM through Week 12
Reported as:
Number · percentage of participants
Percent of Participants With Severe OM at Varying Cumulative Radiation Doses (Gy)
percentage of participantsPlaceboALD518 (160 mg, OL)ALD518 (160 mg, R)ALD518 (320 mg, R)
35 Gy25.057.127.330.0
45 Gy41.771.436.445.0
55 Gy50.071.440.955.0
65 Gy55.650.063.243.8
SecondaryNumber of Participants With Severe OM at Varying Cumulative Radiation Doses (Gy)

The severe OM assessment at a specific cumulative radiation dose (35 Gy, 45 Gy, 55 Gy or 65 Gy) is defined as the first severe OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in the specific cumulative dose of radiation being ≥35 Gy, ≥45 Gy, ≥55 Gy or≥ 65 Gy

Time frame:
Up to 12 weeks
Reported as:
Number · participants
Number of Participants With Severe OM at Varying Cumulative Radiation Doses (Gy)
participantsPlaceboALD518 (160 mg, OL)ALD518 (160 mg, R)ALD518 (320 mg, R)
35 Gy6466
45 Gy10589
55 Gy125911
65 Gy103127
SecondaryDuration of Ulcerative and Severe OM
Time frame:
Up to 12 weeks
Reported as:
Mean · Days
Duration of Ulcerative and Severe OM
DaysPlaceboALD518 (160 mg, OL)ALD518 (160 mg, R)ALD518 (320 mg, R)
Ulcerative42.0 ± 23.1755.1 ± 26.5748.3 ± 16.7138.0 ± 29.53
Severe22.4 ± 23.2835.1 ± 28.0222.7 ± 18.9521.5 ± 25.01
SecondaryTime to Onset of Ulcerative and Severe OM
Time frame:
Up to 12 weeks
Reported as:
Mean · Days
Time to Onset of Ulcerative and Severe OM
DaysPlaceboALD518 (160 mg, OL)ALD518 (160 mg, R)ALD518 (320 mg, R)
Ulcerative23.7 ± 7.0518.7 ± 5.3222.9 ± 5.9724.3 ± 13.37
Severe37.0 ± 11.8126.1 ± 5.7243.1 ± 17.5538.0 ± 15.64
SecondaryALD518 Plasma Concentration at Varying Weeks
Time frame:
Baseline and up to 12 weeks
Reported as:
Mean · ug/mL
ALD518 Plasma Concentration at Varying Weeks
ug/mLALD518 (160 mg, OL)ALD518 (160 mg, R)ALD518 (320 mg, R)
at Baseline0.0 ± 0.000.0 ± 0.000.0 ± 0.00
at Week 224.3 ± 9.9820.6 ± 3.7332.7 ± 5.24
at Week 418.8 ± 6.6240.6 ± 7.5380.6 ± 20.21
at Week 8 (last day of RT)31.6 ± 12.0223.1 ± 6.6446.9 ± 13.74
at Week 12 (4 weeks post RT)16.8 ± 9.5411.5 ± 3.1020.6 ± 14.42
SecondaryOral Mucositis Daily Questionnaire (OMDQ) Overall Health Score at Varying Cumulative Radiation Doses (Gy)

Scored on a scale from 0 (worst possible overall health) to 10 (perfect overall health). Higher scores represent better overall health.

Time frame:
Baseline and up to 12 weeks
Reported as:
Mean · score on a scale
Oral Mucositis Daily Questionnaire (OMDQ) Overall Health Score at Varying Cumulative Radiation Doses (Gy)
score on a scalePlaceboALD518 (160 mg, OL)ALD518 (160 mg, R)ALD518 (320 mg, R)
Baseline6.5 ± 1.958.4 ± 1.407.2 ± 1.666.7 ± 2.35
35 Gy (up to 12 weeks)5.2 ± 2.086.6 ± 2.075.2 ± 2.055.5 ± 1.91
45 Gy (up to 12 weeks)5.6 ± 1.895.7 ± 2.145.4 ± 1.865.4 ± 2.40
55 Gy (up to 12 weeks)5.1 ± 1.965.9 ± 2.545.3 ± 2.225.1 ± 2.27
65 Gy (up to 12 weeks)5.6 ± 1.795.7 ± 3.085.3 ± 2.115.6 ± 2.37
SecondaryFunctional Assessment of Cancer Therapy - Head and Neck (FACT-HN) Questionnaire Overall Assessment Score at Varying Cumulative Radiation Doses (Gy)

The FACT-HN consists of 28 general + 11 head and neck specific items, each rated on a 0 (not at all) to 4 (very much) Likert type scale. The total score ranges from 0 to 148. Higher scores represent better quality of life.

Time frame:
Baseline and up to 12 weeks
Reported as:
Mean · score on a scale
Functional Assessment of Cancer Therapy - Head and Neck (FACT-HN) Questionnaire Overall Assessment Score at Varying Cumulative Radiation Doses (Gy)
score on a scalePlaceboALD518 (160 mg, OL)ALD518 (160 mg, R)ALD518 (320 mg, R)
Baseline116.5 ± 15.86129.4 ± 12.63113.8 ± 19.53111.3 ± 20.94
35 Gy (up to 12 weeks)92.9 ± 20.14100.3 ± 24.1496.2 ± 21.1892.2 ± 19.96
45 Gy (up to 12 weeks)90.6 ± 18.1894.7 ± 30.1489.7 ± 23.4986.6 ± 21.34
55 Gy (up to 12 weeks)89.6 ± 19.3682.3 ± 17.7984.4 ± 25.6781.1 ± 22.13
65 Gy (up to 12 weeks)85.2 ± 18.1393.6 ± 27.5086.5 ± 18.0086.5 ± 23.95
SecondaryFunctional Assessment of Chronic Illness Therapy - Fatigue Questionnaire (FACIT-F) Score at Varying Cumulative Radiation Doses (Gy)

The responses to the 13 items on the FACIT-F questionnaire are each measured on a 5-point Likert scale from 0 (not at all fatigued) to 4 (very much fatigued). The total score ranges from 0 to 52. Higher scores represent less fatigue.

Time frame:
Baseline and up to 12 weeks
Reported as:
Mean · score on a scale
Functional Assessment of Chronic Illness Therapy - Fatigue Questionnaire (FACIT-F) Score at Varying Cumulative Radiation Doses (Gy)
score on a scalePlaceboALD518 (160 mg, OL)ALD518 (160 mg, R)ALD518 (320 mg, R)
Baseline42.5 ± 7.2647.6 ± 3.2642.6 ± 8.6139.7 ± 10.94
35 Gy (up to 12 weeks)31.1 ± 12.5630.1 ± 16.6334.0 ± 9.5931.2 ± 13.56
45 Gy (up to 12 weeks)30.3 ± 11.4228.9 ± 15.6131.2 ± 12.3330.4 ± 11.65
55 Gy (up to 12 weeks)29.9 ± 12.9520.8 ± 14.7028.0 ± 12.9526.8 ± 13.71
65 Gy (up to 12 weeks)29.6 ± 10.8126.8 ± 18.7127.3 ± 9.6529.5 ± 12.40
SecondaryMean Change From Baseline in C-reactive Protein (CRP) Values at Varying Weeks

The level of C-reactive protein (CRP), which can be measured in your blood, increases when there's inflammation in your body.

Time frame:
Baseline and up to 12 weeks
Reported as:
Mean · mg/L
Mean Change From Baseline in C-reactive Protein (CRP) Values at Varying Weeks
mg/LPlaceboALD518 (160 mg)ALD518 (320 mg)
Week 13.50 (3.5 to 3.5)-2.20 (-2.4 to -2.1)-1.15 (-1.7 to -0.6)
Week 28.39 (-13.1 to 73.1)-6.52 (-31.8 to -0.1)-14.74 (-75.6 to -0.2)
Week 312.35 (0.8 to 23.9)-1.75 (-2.3 to -0.4)-14.78 (-29.2 to -0.6)
Week 44.71 (-12.6 to 38.1)-6.82 (-31.8 to -0.1)-14.63 (-75.7 to -0.2)
Week 527.85 (8.6 to 47.1)-15.50 (-42.2 to -1.9)-6.30 (-27.7 to -0.6)
Week 620.52 (-9.5 to 98.2)-6.93 (-31.8 to 0.7)-11.92 (-75.7 to -0.9)
Week 8 (last day of RT)6.51 (-5.3 to 58.8)-7.84 (-42.8 to -0.1)-13.96 (-75.7 to -0.2)
Week 12 (4 weeks post RT)2.99 (-12.6 to 51.2)-8.16 (-42.9 to -0.1)-14.53 (-75.7 to -0.2)

Adverse events

Collected over Up to 15 months for each participant. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/23 (0%)7/23 (30.4%)22/23 (95.7%)
ALD518 (160 mg)4/32 (12.5%)15/32 (46.9%)32/32 (100%)
ALD518 (320 mg)2/21 (9.5%)8/21 (38.1%)21/21 (100%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventPlaceboALD518 (160 mg)ALD518 (320 mg)
NauseaGastrointestinal disorders0/233/320/21
General physical health deteriorationGeneral disorders1/233/320/21
PyrexiaGeneral disorders2/230/320/21
DehydrationMetabolism and nutrition disorders2/231/321/21
Oral painGastrointestinal disorders1/232/320/21
Febrile neutropeniaBlood and lymphatic system disorders0/230/321/21
Acute myocardial infarctionCardiac disorders0/230/321/21
Myocardial infarctionCardiac disorders0/230/321/21
Tongue haemorrhageGastrointestinal disorders0/230/321/21
Abscess limbInfections and infestations0/230/321/21
Most frequent other events
Showing 10 of 225
Most frequent other events
EventPlaceboALD518 (160 mg)ALD518 (320 mg)
ConstipationGastrointestinal disorders13/2322/329/21
NauseaGastrointestinal disorders14/2320/3214/21
Oral candidiasisInfections and infestations11/2318/328/21
Weight decreasedInvestigations7/2311/3211/21
DysgeusiaNervous system disorders12/2311/325/21
VomitingGastrointestinal disorders9/2312/3210/21
DiarrhoeaGastrointestinal disorders10/237/323/21
Dry mouthGastrointestinal disorders10/2311/325/21
White blood cell count decreasedInvestigations2/233/329/21
LeukopeniaBlood and lymphatic system disorders7/2313/326/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboALD518 (160 mg, OL)ALD518 (160 mg, R)ALD518 (320 mg, R)Total
Mean58.8 ± 7.9256.3 ± 11.9358.6 ± 7.4355.1 ± 7.1857.4 ± 8.00
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboALD518 (160 mg, OL)ALD518 (160 mg, R)ALD518 (320 mg, R)Total
Female417113
Male206162163
Region of Enrollment
Region of Enrollment(participants)PlaceboALD518 (160 mg, OL)ALD518 (160 mg, R)ALD518 (320 mg, R)Total
Canada00011
Austria00145
United States765826
Italy305412
Australia912315
Germany5010217
08

Study locations

31 sites
  • Morton Plant Mease Health Care
    Clearwater, Florida 33756, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Karmanos Cancer Center
    Detroit, Michigan 48201, United States
  • Detroit Clinical Research Center
    Farmington Hills, Michigan 48336, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • University of New Mexico Cancer Center
    Albuquerque, New Mexico 87106, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Spartanburg Regional Medical Center
    Spartanburg, South Carolina 29303, United States
  • Cancer Specialists of Southern Texas
    Corpus Christi, Texas 78412, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • VA Puget Sound Health Care Syatem
    Seattle, Washington 98108, United States
  • St. Vincent's Hospital
    Darlinghurst, New South Wales 2010, Australia
  • Calvary Mater Newcastle
    Waratah, New South Wales 2298, Australia
  • Royale Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland, Australia
  • Adelaide Radiotherapy Centre
    Adelaide, South Australia 5037, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia, Australia
  • LKH Graz, HNO Ambulanz
    Graz, Austria
  • Univ. Klinik fur Innere Medizin III
    Salzburg, 5020, Austria
  • Hanusch Krankenhaus
    Vienna, 1140, Austria
  • Cancer Centre of Southeastern Ontario
    Kingston, Ontario K7L 5P9, Canada
  • Maisonneuve-Rosemont Hospital
    Montreal, Quebec H1T 2M4, Canada
  • CHUQ-L'Hotel-Dieu de Quebec
    Quebec, G1R 2J6, Canada
  • Universitatsklinikum Freiburg
    Freiburg, 79106, Germany
  • University Medical School, Saarland
    Homburg, 66424, Germany
  • Uniklinik Koln
    Koln, 50924, Germany
  • A.O. San Paolo - Polo Universitario
    Milan, 20142, Italy
  • Istituto Nazionale dei tumari
    Milan, Italy
  • Azienda Ospedaliero-Universitaria Santa Maria della Misericordia
    Udine, 33100, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Apr 2013 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in May 2021, 8 years 1 month after primary completion. A results delay was requested in Jun 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2011
First posted
Jul 27, 2011
Start
Jul 2011
Primary completionActual
Apr 2013
CompletionActual
Mar 2014
Results delay requested
Jun 23, 2014
Results first posted
May 11, 2021
Last update
May 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01403064
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Jul 27, 2011
Start date
Jul 2011
Primary completion
Apr 2013
Completion
Mar 2014
Results posted
May 11, 2021
Last update
May 11, 2021

Study contacts

Jeffrey Smith, MD FRCP
study director · Alder Biopharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clazakizumab

Start the discussion